
    
      This research study is a Phase II clinical trial. The overall purpose of this study is to
      determine if blinatumomab is safe and effective for treating adult subjects with relapsed or
      refractory indolent B cell NHL.

      Blinatumomab will be infused causing T cells to recognize the Cancer and work against them.
      This approach has been FDA approved for acute lymphocytic leukemia but has not yet been
      approved for lymphoma.
    
  